← All trials
NCT05316701
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 21, 2022
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2028
- First posted
- Apr 7, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 174
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Orca Biosystems, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.